Literature DB >> 2952686

Expression of human lymphocyte antigen (HLA)-DR on tumor cells in basal cell carcinoma.

A Kohchiyama, D Oka, H Ueki.   

Abstract

Immunohistologic studies of eight patients with basal cell carcinoma were undertaken using a series of monoclonal antibodies. In all of the patients, the majority of dermal infiltrates reacted with OKT3 and OKIa1 (HLA-DR), with a slight predominance of OKT4+ helper/inducer T cells (the mean OKT4/OKT8 ratio was 1.8). Both OKT4+ and OKT8+ cells were seen infiltrating the tumor masses. In addition, in five cases, human lymphocyte antigen (HLA)-DR was demonstrated on some tumor cells close to a vast number of HLA-DR+ infiltrates surrounding the carcinoma, but not on epidermal keratinocytes and tumor cells devoid of the HLA-DR+ infiltrates. A considerable number of OKT6+ dendritic cells were also observed surrounding the carcinoma. Staining with OKB7 and OKM1 revealed negligible reactive cells, and virtually none of the dermal infiltrates reacted with Leu-7 (HNK-1). These findings suggest that in addition to varied immunologically competent cells, expression of HLA-DR antigen on tumor cells may participate in a cellular immune reaction, a defense mechanism against tumor cell proliferation in basal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2952686     DOI: 10.1016/s0190-9622(87)70109-1

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

1.  Characterization of the mononuclear infiltrate in Bowen's disease (squamous cell carcinoma in situ). Evidence for a T cell-mediated anti-tumour immune response.

Authors:  J M Habets; B Tank; T van Joost
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

Review 2.  [Basal cell carcinoma and rare form variants].

Authors:  J Liersch; J Schaller
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

3.  Comprehensive and Integrative Analysis of Two Novel SARS-CoV-2 Entry Associated Proteases CTSB and CTSL in Healthy Individuals and Cancer Patients.

Authors:  Yongbiao Huang; Shiyu Li; Shanshan Huang; Jingyao Tu; Xinyi Chen; Lingyan Xiao; Bo Liu; Xianglin Yuan
Journal:  Front Bioeng Biotechnol       Date:  2022-01-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.